The 4 PMOS Phenotypes: Insulin-Resistant, Adrenal, Inflammatory, and Post-Pill

One of the most useful frameworks in functional women's health practice is the recognition that PMOS (formerly PCOS) isn't a single condition. Two clients with the same diagnosis can have completely different underlying drivers, different lab patterns, and different paths to improvement. Treating them with the same protocol is one of the most common reasons clinical care fails.

The 2026 rename to polyendocrine metabolic ovarian syndrome explicitly recognizes the multi-system nature of the condition. That's the perfect moment to formalize a phenotype framework that's been emerging from functional practice for years.

Four phenotypes — overlapping, not mutually exclusive, but clinically distinct enough to drive different intervention priorities:

1. Insulin-Resistant PMOS

The most common phenotype. Maybe 60-70% of PMOS cases have a meaningful insulin resistance component, although the proportion varies based on population. Drives a substantial fraction of the cycle disruption, weight management challenges, and androgen excess symptoms in this group.

Drivers

• Cellular insulin resistance — cells take up glucose less efficiently in response to a given insulin signal
• Compensatory hyperinsulinemia — pancreas produces more insulin to maintain glucose homeostasis
• Elevated insulin then stimulates ovarian theca cells to produce more androgens
• And lowers sex hormone-binding globulin (SHBG), making more free androgens bioavailable

Clinical presentation

• Difficulty losing weight, particularly around the midsection
• Sugar cravings, post-meal energy crashes
• Acanthosis nigricans (darkened skin patches at neck, armpits)
• Skin tags
• Mood swings tied to blood sugar dips
• Irregular or absent ovulation
• Mild to moderate androgen symptoms (acne, hair patterns)

Lab patterns

• Fasting insulin >10 mIU/L (functional range — conventional cutoffs are higher)
• HOMA-IR >2.0
• Fasting glucose may be normal or mildly elevated
• HbA1c often 5.4-6.0% range
• Triglyceride:HDL ratio >2.0
• Low SHBG
• Elevated free testosterone and DHT

Intervention priorities

1. Blood sugar regulation as the foundation — protein-forward meals, minimize refined carbohydrates, structured meal timing
2. Strength training (insulin-sensitizing in a way cardio isn't)
3. Targeted supplements — myo-inositol + d-chiro-inositol (the 40:1 ratio is best-studied), berberine, magnesium, chromium
4. Sleep — insulin sensitivity drops measurably with sleep restriction
5. GLP-1 agonists may be appropriate for some clients (per their medical provider) — these can restore ovulation in this phenotype

2. Adrenal PMOS

Perhaps 20-30% of PMOS cases involve a significant adrenal component — and a subset have primarily adrenal-driven androgen excess rather than ovarian. The adrenal phenotype is one of the most commonly underdiagnosed because conventional workups focus on ovarian androgens (testosterone, free testosterone) and may not adequately assess DHEA-S, the adrenal androgen.

Drivers

• HPA axis dysregulation — chronic stress, sleep deprivation, restricted eating
• Elevated adrenal androgen output (DHEA, DHEA-S)
• Cortisol patterns that may be elevated (early stage) or depleted (later stage)
• Often co-occurs with thyroid pattern shifts

Clinical presentation

• Often lean phenotype — insulin and weight may be normal
• Cycles may be regular but ovulation can still be impaired
• Stress-pattern symptoms — fatigue, sleep disruption, anxiety
• Hair changes — thinning at the temples or crown
• Acne pattern that worsens with stress
• Often high-achieving, perfectionist personality patterns

Lab patterns

• Elevated DHEA-S (above ~250 µg/dL in women under 40)
• Testosterone and free testosterone may be normal or only mildly elevated
• Cortisol patterns abnormal — DUTCH testing useful here
• Often suboptimal thyroid markers (T3, reverse T3)
• Insulin and glucose typically normal

Intervention priorities

1. HPA axis recovery — sleep, stress modulation, vagal tone work
2. Adequate caloric intake — chronic restriction worsens this phenotype
3. Adaptogenic support (ashwagandha, rhodiola — with appropriate screening for thyroid contraindications)
4. Strength training over high-volume cardio
5. Boundaries and pacing work — often the missing intervention
6. Address underlying thyroid patterns if present

3. Inflammatory PMOS

A pattern characterized by systemic inflammation as a primary driver of cycle dysfunction. May or may not have classical insulin resistance, but the inflammatory load is doing the work of disrupting ovulation and amplifying androgen signaling.

Drivers

• Chronic low-grade systemic inflammation
• Often gut-driven — food sensitivities, dysbiosis, leaky gut
• Frequently co-occurring autoimmune patterns
• Environmental toxin load (endocrine disruptors)
• Stress-driven inflammation as a secondary driver

Clinical presentation

• Often diagnoses or symptoms of co-occurring autoimmune conditions
• GI symptoms — bloating, IBS-like patterns, food sensitivities
• Skin conditions beyond acne — eczema, rosacea, psoriasis
• Joint pain, headaches, brain fog
• Allergies and histamine-pattern symptoms
• Cycle symptoms often worsened cyclically by inflammatory load

Lab patterns

• Elevated hs-CRP (above 1.0 mg/L is functional-range concerning)
• Elevated ferritin (often higher than iron status alone would predict)
• Antibody patterns may be present (thyroid, gluten)
• Lipid markers may show inflammatory pattern (oxidized LDL elevated)
• Stool testing reveals dysbiosis or specific pathogens
• Vitamin D often low

Intervention priorities

1. Gut healing protocols — comprehensive elimination phase, targeted microbiome support, possibly autoimmune protocol
2. Anti-inflammatory diet — omega-3 focus, polyphenols, low inflammatory triggers
3. Vitamin D repletion to optimal levels (50-70 ng/mL)
4. Environmental toxin reduction — water filtration, cleaner personal care products, food source quality
5. Stress management to reduce inflammatory amplification
6. Address co-occurring conditions (often thyroid, autoimmune)

4. Post-Pill PMOS

A pattern that emerges after discontinuing hormonal birth control. May be temporary (related to the post-pill recalibration period) or unmasked (reveals underlying PMOS that the pill was chemically managing). The 2025 post-pill syndrome research lends credibility to this as a distinct clinical pattern.

Drivers

• HPO axis recalibration after years of contraceptive suppression
• Transient hyperandrogenism as the body resumes its own hormone production
• Possible underlying PMOS that was masked by the pill
• Nutrient depletion from contraceptive use (B vitamins, magnesium, zinc)

Clinical presentation

• Symptoms begin within 1-6 months of discontinuing the pill
• Cystic acne, often dramatic, around the chin/jawline
• Scalp hair shedding
• Cycles irregular or absent
• May be the first time the client has experienced any of these — they started the pill before their natural cycle was established
• Mood changes — anxiety, depression patterns appearing for the first time

Lab patterns

• Transiently elevated testosterone (often normalizes in 6-12 months)
• Elevated LH:FSH ratio in some cases
• Often nutrient depletion — low magnesium, B12, zinc
• SHBG may be low post-discontinuation
• Insulin pattern variable

Intervention priorities

1. Aggressive nutrient repletion — comprehensive multivitamin, methylated B complex, magnesium, zinc
2. Liver and gut support during HPO recalibration
3. Cycle tracking to establish what's actually happening
4. Time — many clients need 6-12 months of support before the picture fully stabilizes
5. After 6-12 months, re-assess: if symptoms persist, the client likely has one of the other phenotypes (insulin-resistant, adrenal, or inflammatory) underneath

Assessment workflow

For a new PMOS client, work through the phenotype assessment in this order:

1. History first. Pill history, family patterns, when symptoms began, current symptom cluster — these alone often identify the dominant phenotype.
2. Body composition and metabolic clues. Weight patterns, body composition, sugar cravings, energy patterns — insulin-resistant signals.
3. Stress and lifestyle. Sleep, work pattern, restriction patterns, exercise — adrenal signals.
4. Inflammatory clues. Other autoimmune diagnoses, GI symptoms, allergies, skin conditions beyond acne — inflammatory signals.
5. Lab confirmation. A focused panel based on the dominant phenotype suspected, rather than ordering everything at once.

Most clients show predominantly one phenotype but have elements of others. The framework guides priority, not exclusion.

Why this matters

The phenotype framework changes the conversation with clients from “you have PMOS, here's the PMOS protocol” to “your particular pattern is X, and that means we'll focus on Y first.” It validates why their previous attempts at generic PMOS protocols may not have worked. And it builds the kind of clinical specificity that distinguishes practitioner work from general wellness advice.

With the 2026 rename in place, the framework finally has a name that reflects what it's describing. PMOS is multisystem. The phenotypes are how that multisystem nature actually shows up in real clients.